

AWARD NUMBER: W81XWH-16-1-0698

TITLE: A Novel Urinary Catheter with Tailorable Bactericidal Behavior

PRINCIPAL INVESTIGATOR: Dr. Hassan Razvi

CONTRACTING ORGANIZATION: LONDON HEALTH SCIENCES CENTRE RESEARCH
London N6C 2R5

REPORT DATE: October 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.
PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE October 2017		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2016 - 29 Sep 2017	
4. TITLE AND SUBTITLE A Novel Urinary Catheter with Tailorable Bactericidal Behavior				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-16-1-0698	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr Hassan Razvi Dr Jeremy Burton E-Mail: Hassan.Razvi@sjhc.london.on.ca				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) AND ADDRESS(ES) LONDON HEALTH SCIENCES CENTRE RESEARCH I 750 BASE LINE RE LONDON N6C 2R5 CANADA				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This is a project being conducted at two sites. Our US collaborator's role is the development of novel biomaterials that will be used to manufacture urinary catheters. Our portion of the project is the evaluation of these urinary catheters first in vitro, and then in an in vivo animal model. We have established animal protocols and written ethics in place to be able to undertake this work once we receive the materials from our research collaborator.					
15. SUBJECT TERMS None listed					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER <i>(include area code)</i>

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	5
5. Changes/Problems.....	5
6. Products.....	6
7. Participants & Other Collaborating Organizations.....	6
8. Special Reporting Requirements.....	7
9. Appendices.....	7

1. INTRODUCTION:

Catheter-associated urinary tract infections (CAUTIs) are the most common nosocomial infection globally accounting for roughly 40% of all reported healthcare-associated infections (HAIs). Developing more biocompatible and infection-resistant urinary catheter materials may help to reduce the morbidity and mortality associated with CAUTIs. We believe that the proposed research has the potential to significantly reduce costs (product and care) and improve outcomes for military and civilian populations. In this project there are six specific aims that will be evaluated to test the silicone composite materials that employ a novel antimicrobial ion exchange (AM-IE) resin system. Four of the aims are (*in vitro*) to be carried out at Iasis Molecular Sciences and are intended to optimize device configurations. Two specific aims to be carried out by ourselves (Razvi & Burton) are intended to evaluate the *in vivo* performance of these devices in a rabbit model.

2. KEYWORDS:

CAUTI, urinary tract infection, catheter, infection, silicone

3. ACCOMPLISHMENTS:

- **What were the major goals of the project?**

Our contribution to the project is to test the novel polymers that have been developed using *in vitro* and *in vivo* evaluations. At this time we are awaiting delivery of the materials in order to begin our portion of the study. (Aims 4-8).

Specific Aim 1 – To synthesize coating polymers, identify an optimal lubricious coating, and optimize antiseptic loading

Specific Aim 2: Synthesis of AM-IE resins, fabrication, and testing of ten composite silicone test articles

Specific Aim 3: *In Vitro* characterization of six AM-IE silicone composites with antiseptic lubricious coating

OUR AIMS START HERE

Specific Aim 4: Determination of *in vitro* efficacy of the candidate composites

Specific Aim 5: *In vivo* rabbit ureteral stent model

Specific Aim 6: *In vivo* rabbit urethral catheter model

Specific Aim 7: Histopathological evaluation of kidney, bladder and ureter tissue samples

Specific Aim 8: Reporting and results evaluation for future clinical evaluations

- **What was accomplished under these goals?**

We have derived animal protocols and ethics for our *in vivo* studies.

- **What opportunities for training and professional development has the project provided?**

NA

- **How were the results disseminated to communities of interest?**

Nothing to report.

- **What do you plan to do during the next reporting period to accomplish the goals?**

Our part of the project will be well underway by this time next year. We anticipate we will have completed our in vitro studies, and the animal studies will be underway.

4. IMPACT

- **What was the impact on the development of the principal discipline(s) of the project?**

Nothing to Report.

- **What was the impact on other disciplines?**

Nothing to Report.

- **What was the impact on technology transfer?**

Nothing to Report.

- **What was the impact on society beyond science and technology?**

Nothing to Report.

5. CHANGES/PROBLEMS:

- **Changes in approach and reasons for change**
- **Actual or anticipated problems or delays and actions or plans to resolve them**
- **Changes that had a significant impact on expenditures**
- **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**
- **Significant changes in use or care of human subjects**
- **Significant changes in use or care of vertebrate animals.**
- **Significant changes in use of biohazards and/or select agents**

Nothing to Report.

6. PRODUCTS

- *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state "Nothing to Report."*
 - **Publications, conference papers, and presentations**
 - **Journal publications.**
 - **Books or other non-periodical, one-time publications.**
 - **Other publications, conference papers, and presentations.**

Nothing to Report.

- **Website(s) or other Internet site(s)**
- **Technologies or techniques**
- **Inventions, patent applications, and/or licenses**
- **Other Products**

Nothing to Report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

- **What individuals have worked on the project?**

Name:	<i>Patricia Rosas Arellano</i>
Project Role:	<i>Coordinator</i>
Researcher Identifier (e.g. ORCID ID):	<i>NA</i>
Nearest person month worked:	<i>3</i>
Contribution to Project:	<i>Dr Arellano has coordinated documents and protocols</i>
Funding Support:	<i>This award</i>

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report.

- **What other organizations were involved as partners?**

Nothing to Report.

8. SPECIAL REPORTING REQUIREMENTS

Nothing to Report.

9. APPENDICES

Nothing to Report.